Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum : results from IMPAACT P1026s
Physiological changes during pregnancy may alter the pharmacokinetics (PK) of antituberculosis drugs. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026s was a multicenter, phase IV, observational, prospective PK and safety study of antiretroviral and antituberculosis drugs administered as part of clinical care in pregnant persons living with and without HIV. We assessed the effects of pregnancy on rifampin, isoniazid, ethambutol, and pyrazinamide PK in pregnant and postpartum (PP) persons without HIV treated for drug-susceptible tuberculosis disease. Daily antituberculosis treatment was prescribed following World Health Organization-recommended weight-band dosing guidelines. Steady-state 12-hour PK profiles of rifampin, isoniazid, ethambutol, and pyrazinamide were performed during second trimester (2T), third trimester (3T), and 2-8 of weeks PP. PK parameters were characterized using noncompartmental analysis, and comparisons were made using geometric mean ratios (GMRs) with 90% confidence intervals (CI). Twenty-seven participants were included: 11 African, 9 Asian, 3 Hispanic, and 4 mixed descent. PK data were available for 17, 21, and 14 participants in 2T, 3T, and PP, respectively. Rifampin and pyrazinamide AUC0-24 and C max in pregnancy were comparable to PP with the GMR between 0.80 and 1.25. Compared to PP, isoniazid AUC0-24 was 25% lower and C max was 23% lower in 3T. Ethambutol AUC0-24 was 39% lower in 3T but limited by a low PP sample size. In summary, isoniazid and ethambutol concentrations were lower during pregnancy compared to PP concentrations, while rifampin and pyrazinamide concentrations were similar. However, the median AUC0-24 for rifampin, isoniazid, and pyrazinamide met the therapeutic targets. The clinical impact of lower isoniazid and ethambutol exposure during pregnancy needs to be determined.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 67(2023), 11 vom: 15. Nov., Seite e0073723 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Van Schalkwyk, Marije [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/aac.00737-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363746854 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363746854 | ||
| 003 | DE-627 | ||
| 005 | 20240210232810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/aac.00737-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM363746854 | ||
| 035 | |a (NLM)37882552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Van Schalkwyk, Marije |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum |b results from IMPAACT P1026s |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Physiological changes during pregnancy may alter the pharmacokinetics (PK) of antituberculosis drugs. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026s was a multicenter, phase IV, observational, prospective PK and safety study of antiretroviral and antituberculosis drugs administered as part of clinical care in pregnant persons living with and without HIV. We assessed the effects of pregnancy on rifampin, isoniazid, ethambutol, and pyrazinamide PK in pregnant and postpartum (PP) persons without HIV treated for drug-susceptible tuberculosis disease. Daily antituberculosis treatment was prescribed following World Health Organization-recommended weight-band dosing guidelines. Steady-state 12-hour PK profiles of rifampin, isoniazid, ethambutol, and pyrazinamide were performed during second trimester (2T), third trimester (3T), and 2-8 of weeks PP. PK parameters were characterized using noncompartmental analysis, and comparisons were made using geometric mean ratios (GMRs) with 90% confidence intervals (CI). Twenty-seven participants were included: 11 African, 9 Asian, 3 Hispanic, and 4 mixed descent. PK data were available for 17, 21, and 14 participants in 2T, 3T, and PP, respectively. Rifampin and pyrazinamide AUC0-24 and C max in pregnancy were comparable to PP with the GMR between 0.80 and 1.25. Compared to PP, isoniazid AUC0-24 was 25% lower and C max was 23% lower in 3T. Ethambutol AUC0-24 was 39% lower in 3T but limited by a low PP sample size. In summary, isoniazid and ethambutol concentrations were lower during pregnancy compared to PP concentrations, while rifampin and pyrazinamide concentrations were similar. However, the median AUC0-24 for rifampin, isoniazid, and pyrazinamide met the therapeutic targets. The clinical impact of lower isoniazid and ethambutol exposure during pregnancy needs to be determined | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a drug-susceptible tuberculosis | |
| 650 | 4 | |a ethambutol | |
| 650 | 4 | |a isoniazid | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a pyrazinamide | |
| 650 | 4 | |a rifampin | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Ethambutol |2 NLM | |
| 650 | 7 | |a 8G167061QZ |2 NLM | |
| 650 | 7 | |a Isoniazid |2 NLM | |
| 650 | 7 | |a V83O1VOZ8L |2 NLM | |
| 650 | 7 | |a Pyrazinamide |2 NLM | |
| 650 | 7 | |a 2KNI5N06TI |2 NLM | |
| 650 | 7 | |a Rifampin |2 NLM | |
| 650 | 7 | |a VJT6J7R4TR |2 NLM | |
| 700 | 1 | |a Bekker, Adrie |e verfasserin |4 aut | |
| 700 | 1 | |a Decloedt, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiajia |e verfasserin |4 aut | |
| 700 | 1 | |a Theron, Gerhard B |e verfasserin |4 aut | |
| 700 | 1 | |a Cotton, Mark F |e verfasserin |4 aut | |
| 700 | 1 | |a Eke, Ahizechukwu C |e verfasserin |4 aut | |
| 700 | 1 | |a Cressey, Tim R |e verfasserin |4 aut | |
| 700 | 1 | |a Shapiro, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Bacon, Kira |e verfasserin |4 aut | |
| 700 | 1 | |a Knowles, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a George, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Browning, Renee |e verfasserin |4 aut | |
| 700 | 1 | |a Chakhtoura, Nahida |e verfasserin |4 aut | |
| 700 | 1 | |a Rungruengthanakit, Kittipong |e verfasserin |4 aut | |
| 700 | 1 | |a Wiesner, Lubbe |e verfasserin |4 aut | |
| 700 | 1 | |a Capparelli, Edmund V |e verfasserin |4 aut | |
| 700 | 1 | |a Stek, Alice M |e verfasserin |4 aut | |
| 700 | 1 | |a Mirochnick, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Best, Brookie M |e verfasserin |4 aut | |
| 700 | 0 | |a IMPAACT P1026s Protocol Team |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 67(2023), 11 vom: 15. Nov., Seite e0073723 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2023 |g number:11 |g day:15 |g month:11 |g pages:e0073723 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/aac.00737-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2023 |e 11 |b 15 |c 11 |h e0073723 | ||